3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Sezary Syndrome
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Leukemia
1
Interventions
venetoclax
5
Dexamethasone
5
Cytarabine
3
Cyclophosphamide
3
Vincristine
2
Decitabine
2
trametinib
1
ruxolitinib
1
pegaspargase
1
nilotinib
1
navitoclax
1
merphos
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
capivasertib
1
blinatumomab
1
Vorinostat
1
Spinal Puncture
1
Specimen Handling
1
Mitoxantrone
1
Methotrexate
1
Magnetic Resonance Spectroscopy
1
Dasatinib
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
×
navitoclax
×
Clear all
NCT05740449
2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2
Withdrawn